Glucophage (metformin)

Glucophage (metformin) is filed as Biguanide. The sections below restate public label fields stored for this profile.

Class
Biguanide
Generic name
metformin
Route
ORAL
Dosage forms
3 DOSAGE FORMS AND STRENGTHS GLUCOPHAGE Tablets: 500 mg, 850 mg, and 1000 mg (3) GLUCOPHAGE XR Extended-Release Tablets: 500 mg and 750 mg (3) GLUCOPHAGE is available as: Tablets: 500 mg round, white to off-white, film-coated debossed with "BMS 6060" around the periphery on one side and "500" debossed across the face of the other side. Tablets: 850 mg round, white to off-white, film-coated debossed with "BMS 6070" around the periphery on one side and "850" debossed across the face of the other side. Tablets: 1000 mg white, oval, biconvex, film-coated with "BMS 6071" debossed on one side and "1000" debossed on the opposite side and with a bisect line on both sides. GLUCOPHAGE XR is available as: Extended-release tablets: 500 mg white to off-white, capsule shaped, biconvex, with "BMS 6063" debossed on one side and "500" debossed across the face of the other side. Extended-release tablets: 750 mg pale red and may have a mottled appearance, capsule shaped, biconvex, with "BMS 6064" debossed on one side and "750" debossed on the other side.
Generic available
Yes
Manufacturer
Bristol-Myers Squibb Company
Boxed warning
Yes

Approved uses

1 INDICATIONS AND USAGE GLUCOPHAGE is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. GLUCOPHAGE XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. GLUCOPHAGE is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. (1) GLUCOPHAGE XR is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1)

Boxed warning

WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions ( 5.1 )]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [see Dosage and Administration ( 2.3 ), (2.7), Contraindications ( 4 ), Warnings and Precautions ( 5.1 )]. If metformin-associated lactic acidosis is suspected, immediately discontinue GLUCOPHAGE or GLUCOPHAGE XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions ( 5.1 )]. WARNING: LACTIC ACIDOSIS See full prescribing information for complete boxed warning. Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL. ( 5.1 ) Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. ( 5.1 ) If lactic acidosis is suspected, discontinue GLUCOPHAGE/ GLUCOPHAGE XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. ( 5.1 )

Warnings and precautions

5 WARNINGS AND PRECAUTIONS Lactic Acidosis: See boxed warning. (5.1) Vitamin B 12 Deficiency: Metformin may lower vitamin B 12 levels.Measure hematological parameters annually and vitamin B 12 at 2 to 3 year intervals and manage any abnormalities. (5.2) Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Lower dose of insulin or insulin secretagogue may be required (5.3) 5.1 Lactic Acidosis There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypotension and resistant bradyarrhythmias have occurred with severe acidosis. Metformin-associated lactic acidosis was characterized by elevated blood lactate concentrations (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate: pyruvate ratio; metformin plasma levels were generally >5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk. If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of GLUCOPHAGE/GLUCOPHAGE XR. In GLUCOPHAGE/GLUCOPHAGE XR treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin hydrochloride is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions). Hemodialysis has often resulted in reversal of symptoms and recovery. Educate patients and their families about the symptoms of lactic acidosis and, if these symptoms occur, instruct them to discontinue GLUCOPHAGE/GLUCOPHAGE XR and report these symptoms to their healthcare provider. For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below: Renal impairment—The postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment. The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patient’s renal function include [see Dosage and Administration (2.1) , Clinical Pharmacology (12.3) ] Before initiating GLUCOPHAGE/GLUCOPHAGE XR, obtain an estimated glomerular filtration rate (eGFR). GLUCOPHAGE/GLUCOPHAGE XR is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m 2 [see Contraindications (4) ] Initiation of GLUCOPHAGE/GLUCOPHAGE XR is not recommended in patients with eGFR between 30-45 mL/min/1.73 m 2 . Obtain an eGFR at least annually in all patients taking GLUCOPHAGE/ GLUCOPHAGE XR. In patients at risk for the development of renal impairment (e.g., the elderly), renal function should be assessed more frequently. In patients taking GLUCOPHAGE/GLUCOPHAGE XR whose eGFR falls below 45 mL/min/1.73 m 2 , assess the benefit and risk ofcontinuing therapy. Drug interactions — The concomitant use of GLUCOPHAGE/GLUCOPHAGE XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance, or increase metformin accumulation. Consider more frequent monitoring of patients. Age 65 or greater — The risk of metformin-associated lactic acidosis increases with the patient’s age because elderly patients have a greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Assess renal function more frequently in elderly patients. Radiologic studies with contrast — Administration of intravascular iodinated contrast agents in metformin-treated patients has led to an acute decrease in renal function and the occurrence of lactic acidosis. Stop GLUCOPHAGE/GLUCOPHAGE XR at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and restart GLUCOPHAGE/GLUCOPHAGE XR if renal function is stable. Surgery and other procedures — Withholding of food and fluids during surgical or other procedures may increase the risk for volume depletion, hypotension, and renal impairment. GLUCOPHAGE/GLUCOPHAGE XR should be temporarily discontinued while patients have restricted food and fluid intake. Hypoxic states — Several of the postmarketing cases of metformin-associated lactic acidosis occurred in the setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may cause prerenal azotemia. When such an event occurs, discontinue GLUCOPHAGE/GLUCOPHAGE XR. Excessive alcohol intake — Alcohol potentiates the effect of metformin on lactate metabolism. Patients should be warned against excessive alcohol intake while receiving GLUCOPHAGE/GLUCOPHAGE XR. Hepatic impairment — Patients with hepatic impairment have developed cases of metformin-associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, avoid use of GLUCOPHAGE/GLUCOPHAGE XR in patients with clinical or laboratory evidence of hepatic disease. 5.2 Vitamin B12 Deficiency In GLUCOPHAGE clinical trials of 29-week duration, a decrease to subnormal levels of previously normal serum vitamin B 12 levels was observed in approximately 7% of patients. Such decrease, possibly due to interference with B 12 absorption from the B 12 -intrinsic factor complex, may be associated with anemia but appears to be rapidly reversible with discontinuation of GLUCOPHAGE or vitamin B 12 supplementation. Certain individuals (those with inadequate vitamin B 12 or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B 12 levels. Measure hematologic parameters on an annual basis and vitamin B 12 at 2 to 3 year intervals in patients on GLUCOPHAGE/GLUCOPHAGE XR and manage any abnormalities [see Adverse Reactions ( 6.1 )]. 5.3 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues Insulin and insulin secretagogues (e.g., sulfonylurea) are known to cause hypoglycemia. GLUCOPHAGE/GLUCOPHAGE XR may increase the risk of hypoglycemia when combined with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with GLUCOPHAGE/GLUCOPHAGE XR [see Drug Interactions ( 7 )]. 5.4 Macrovascular Outcomes There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with GLUCOPHAGE/GLUCOPHAGE XR.

Contraindications

4 CONTRAINDICATIONS Severe renal impairment (eGFR below 30 mL/min/1.73 m 2 ) ( 4 , 5.1 ) Hypersensitivity to metformin (4) Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. (4) GLUCOPHAGE and GLUCOPHAGE XR are contraindicated in patients with: Severe renal impairment (eGFR below 30 mL/min/1.73 m2) [see Warnings and Precautions ( 5.1 )]. Hypersensitivity to metformin. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.

Common side effects

Diarrhea (>5.0%); Nausea/vomiting (>5.0%); Flatulence (>5.0%); Asthenia (>5.0%); Indigestion (>5.0%); Abdominal discomfort (>5.0%); Headache (>5.0%)

Adverse reactions

For GLUCOPHAGE/GLUCOPHAGE XR, the most common adverse reactions (>5.0%) are diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Dosage and administration

2 DOSAGE AND ADMINISTRATION Adult Dosage for GLUCOPHAGE: Starting dose: 500 mg orally twice a day or 850 mg once a day, with meals Increase the dose in increments of 500 mg weekly or 850 mg every 2 weeks, up to a maximum dose of 2550 mg per day, given in divided doses (2.1) Doses above 2000 mg may be better tolerated given 3 times a day with meals (2.1) Adult Dosage for GLUCOPHAGE XR: Swallow GLUCOPHAGE XR tablets whole and never crush, cut or chew (2.1) Starting dose: 500 mg orally once daily with the evening meal (2.1) Increase the dose in increments of 500 mg weekly, up to a maximum of 2000 mg once daily with the evening meal (2.1) Patients receiving GLUCOPHAGE may be switched to GLUCOPHAGE XR once daily at the same total daily dose, up to 2000 mg once daily (2.1) Pediatric Dosage for GLUCOPHAGE: Starting dose: 500 mg orally twice a day, with meals (2.2) Increase dosage in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses twice daily (2.2) Renal Impairment: Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) (2.3) o Do not use in patients with eGFR below 30 mL/minute/1.73 m 2 (2.3) o Initiation is not recommended in patients with eGFR between 30-45 mL/minute/1.73 m 2 (2.3) o Assess risk/benefit of continuing if eGFR falls below 45 mL/minute/1.73 m 2 (2.3) o Discontinue if eGFR falls below 30 mL/minute/1.73 m 2 (2.3) Discontinuation for Iodinated Contrast Imaging Procedures: GLUCOPHAGE/GLUCOPHAGE XR may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures (2.4) 2.1 Adult Dosage GLUCOPHAGE The recommended starting dose of GLUCOPHAGE is 500 mg orally twice a day or 850 mg once a day, given with meals. Increase the dose in increments of 500 mg weekly or 850 mg every 2 weeks on the basis of glycemic control and tolerability, up to a maximum dose of 2550 mg per day, given in divided doses. Doses above 2000 mg may be better tolerated given 3 times a day with meals. GLUCOPHAGE XR Swallow GLUCOPHAGE XR tablets whole and never crush, cut or chew. The recommended starting dose of GLUCOPHAGE XR is 500 mg orally once daily with the evening meal. Increase the dose in increments of 500 mg weekly on the basis of glycemic control and tolerability, up to a maximum of 2000 mg once daily with the evening meal. If glycemic control is not achieved with GLUCOPHAGE XR 2000 mg once daily, consider a trial of GLUCOPHAGE XR 1000 mg twice daily. If higher doses are required, switch to GLUCOPHAGE at total daily doses up to 2550 mg administered in divided daily doses, as described above. Patients receiving GLUCOPHAGE may be switched to GLUCOPHAGE XR once daily at the same total daily dose, up to 2000 mg once daily. 2.2 Pediatric Dosage for GLUCOPHAGE The recommended starting dose of GLUCOPHAGE for pediatric patients 10 years of age and older is 500 mg orally twice a day, given with meals. Increase dosage in increments of 500 mg weekly on the basis of glycemic control and tolerability, up to a maximum of 2000 mg per day, given in divided doses twice daily. 2.3 Recommendations for Use in Renal Impairment Assess renal function prior to initiation of GLUCOPHAGE/GLUCOPHAGE XR and periodically thereafter. GLUCOPHAGE/GLUCOPHAGE XR is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m2. Initiation of GLUCOPHAGE/GLUCOPHAGE XR in patients with an eGFR between 30 – 45 mL/minute/1.73 m2 is not recommended. In patients taking GLUCOPHAGE/GLUCOPHAGE XR whose eGFR later falls below 45 mL/min/1.73 m2, assess the benefit risk of continuing therapy. Discontinue GLUCOPHAGE/GLUCOPHAGE XR if the patient’s eGFR later falls below 30 mL/minute/1.73 m2 [see Warnings and Precautions (5.1) ] 2.4 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue GLUCOPHAGE/GLUCOPHAGE XR at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart GLUCOPHAGE/GLUCOPHAGE XR if renal function is stable.

Drug interactions

Carbonic anhydrase inhibitors may increase risk of lactic acidosis. Consider more frequent monitoring (7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use (7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake (7)

Patient counseling

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Lactic Acidosis: Explain the risks of lactic acidosis, its symptoms, and conditions that predispose to its development. Advise patients to discontinue GLUCOPHAGE/GLUCOPHAGE XR immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgias, malaise, unusual somnolence or other nonspecific symptoms occur. Counsel patients against excessive alcohol intake and inform patients about importance of regular testing of renal function while receiving GLUCOPHAGE/GLUCOPHAGE XR. Instruct patients to inform their doctor that they are taking GLUCOPHAGE/GLUCOPHAGE XR prior to any surgical or radiological procedure, as temporary discontinuation may be required [see Warnings and Precautions ( 5.1 )]. Hypoglycemia Inform patients that hypoglycemia may occur when GLUCOPHAGE/GLUCOPHAGE XR is coadministered with oral sulfonylureas and insulin. Explain to patients receiving concomitant therapy the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development [see Warnings and Precautions ( 5.3 )]. Vitamin B12 Deficiency: Inform patients about importance of regular hematological parameters while receiving GLUCOPHAGE/GLUCOPHAGE XR [see Warnings and Precautions ( 5.2 )]. Females of Reproductive Age: Inform females that treatment with GLUCOPHAGE/GLUCOPHAGE XR may result in ovulation in some premenopausal anovulatory women which may lead to unintended pregnancy [see Use in Specific Populations ( 8.3) ]. GLUCOPHAGE XR Administration Information: Inform patients that GLUCOPHAGE XR must be swallowed whole and not crushed, cut, or chewed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft mass that may resemble the original tablet. Distributed by: Bristol-Myers Squibb Company Princeton, NJ 08543 USA GLUCOPHAGE® is a registered trademark of Merck Santé S.A.S., a subsidiary of Merck KGaA of Darmstadt, Germany, licensed to Bristol-Myers Squibb Company. 1390866A0 Rev May 2018

Common questions

What is Glucophage approved to treat?

According to its FDA label, Glucophage (metformin) is approved for: 1 INDICATIONS AND USAGE GLUCOPHAGE is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. GLUCOPHAGE XR is indicated as an adjunct to diet and exercise to improve glycem… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Glucophage?

Glucophage (metformin) belongs to the Biguanide class of medications.

What form does Glucophage come in?

The FDA label lists Glucophage (metformin) as: 3 DOSAGE FORMS AND STRENGTHS GLUCOPHAGE Tablets: 500 mg, 850 mg, and 1000 mg (3) GLUCOPHAGE XR Extended-Release Tablets: 500 mg and 750 mg (3) GLUCOPHAGE is available as: Tablets: 500 mg round, white to off-white, film-coated debossed with "BMS 6060" around the periphery on one side and "500" debossed across the face of the other side. Tablets: 850 mg round, white to off-white, film-coated debossed with "BMS 6070" around the periphery on one side and "850" debossed across the face of the other side. Tablets: 1000 mg white, oval, biconvex, film-coated with "BMS 6071" debossed on one side and "1000" debossed on the opposite side and with a bisect line on both sides. GLUCOPHAGE XR is available as: Extended-release tablets: 500 mg white to off-white, capsule shaped, biconvex, with "BMS 6063" debossed on one side and "500" debossed across the face of the other side. Extended-release tablets: 750 mg pale red and may have a mottled appearance, capsule shaped, biconvex, with "BMS 6064" debossed on one side and "750" debossed on the other side.; oral route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Glucophage?

Yes. A generic version of Glucophage (metformin) is available in the U.S. Ask your pharmacist about substitution.

Does Glucophage have a Boxed Warning?

Yes. The FDA label for Glucophage (metformin) carries a Boxed Warning. Excerpt: "WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.

How much does Glucophage cost?

Public CMS NADAC pricing for Glucophage (metformin) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Glucophage currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Glucophage (metformin) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Glucophage approved by the FDA?

The FDA record lists the approval date for Glucophage (metformin) as 1995-03-03.

Who makes Glucophage?

The FDA label lists Bristol-Myers Squibb Company as a labeler/manufacturer of Glucophage (metformin). Multiple firms may market generics of the same molecule.

How should Glucophage be stored?

The FDA label states: "Storage Store at 20°–25°C (68°–77°F); excursions permitted to 15°–30°C (59°–86°F). [See USP Controlled Room Temperature] Dispense in light-resistant containers." Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…